28 Nov

Oncotarget: informative and convenient

I will mainly talk about this particular journal, Oncotarget. It is a biomedical journal which covers research on all aspects of oncology. I discovered they also publish subsections on topics beyond oncology like aging, microbiology, and chromosomes among others. One publication that fascinated me was on the benefit of neoadjuvant chemotherapy and pCR for patients with advanced Triple-negative breast cancer. It highlights the role of the procedures in prolonging the lives of the patients. Triple-negative breast cancer is characterized by a lack of estrogen and progesterone receptors. Besides, there is no expression of human epidermal growth factor receptor 2. The publication addresses the factors related to short-term and long-term effects of the treatment. Primarily, the results focused on the survival of the patients.

The peer-reviewed journal is published twice per week. Interestingly, I noted that seven volumes had been released so far with 324 issues available. Currently, it’s in the eighth volume. What fascinated me about this journal is its free access. It fosters applications of both basic and clinical science in combating diseases. Being under the realm of the most prominent scientists, they have helped all researchers contribute to the progress of science.

I realized there are efforts in place to become the first research journal to publish on PubMed a few days after being released online. This is through a partnership with the National Library of Medicine. Furthermore, the journal gives every paper a particular aspect of identifying with. This is through recommendations put in place by the Committee on Publication Ethics. In essence, Oncotarget has provided information to people from all walks of life ranging from researchers, medical professionals, and patients among others.

I ventured into an earlier article on Spe 19 2017. This particular piece assured readers that all its scientific publications would be readily available. Publishing twice a week will allow the publication cover the full range of subjects within the field of biomedicine. Also, it will give more researchers a platform to publish their work. Oncotarget will still be available on PubMed, PubMed Central, and ISI/Web of Science among others. As a person with a profound interest in biology and medicine, I can attest that you will capture a lot in Oncotarget.

 

18 May

Oncotarget: Towards Free Access to Information

Since its establishment in 2010, Oncotarget has grown in stature within scientific circles to become one of the leading scientific journals in the world. The medical journal published weekly under the sponsorship of Gordon Research Conference by Impact, primarily focuses on research-based and peer reviewed articles on cancer. However, over the years the journal has expanded the fields of its focus. Informed by the interconnectivity of cancer and other fields, the journal currently accepts articles on cellular and molecular biology among other fields. This ensures that the journal engages in a full frontal approach towards cancer: a scourge that has becoming a leading cause of deaths annually across the globe.

Oncotarget is committed towards ensuring that information on cancer and various related fields is available not only to the scientific community, but also to the general population. Towards this end, the journal operates an open source entity where all interested can submit and retrieved the peer-reviewed and researched articles online for free. Free generation and dispensation of information on cancer, other related conditions and other medical conditions, in general, is a major boost for the much-needed success towards finding a lasting and effective cure and therapies. Check the journal at SCImago Journal & Country Rank.

Quality Measures

Oncotarget has relatively positive ratings, which is reflective of the quality measures taken by the management of the journal. Before publication, all the articles undergo a rigorous peer review process carried out by multiple peers. These highly qualified professionals thoroughly vet the content of the articles before they are published for public consumption. In addition, the journal has highly qualified professionals sitting on its editorial board. The editorial board is composed of experienced scholars. Some of them including Mikhail Blagosklonny, its current editor-in-chief is a research scientist and professor with years of scholarly experience as an oncology specialist. Others are specialists in biology, cellular and molecular biology. This allows the journal to publish thoroughly vetted articles tackling different issues across various fields.

These quality measures have led to a Q1 ranking by Scopus/SJR. This is the highest ranking for journals by the entity. With over ten thousand citations for its articles, Oncotarget is one of the most popular journals globally when citation ratings are compared. Moreover, the journal has an impressive impact factor of 5.008 despite its relatively lifespan.

Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget